News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cengent Therapeutics Signs Genes-To-Leads Drug Discovery Contract With Dynamis Therapeutics



10/19/2005 5:12:11 PM

Cengent Therapeutics, a structure-guided drug discovery company, announced today the signing of a Genes-To-Leads(R) drug discovery contract with Dynamis Therapeutics, Inc., a Pennsylvania based biotechnology company. Under the agreement, Cengent will apply its proprietary platform lead identification technology, Genes To Leads(R), to screen for drug candidates against diabetic related kidney and heart disease, blindness and neuropathy. The proprietary drug target of Dynamis Therapeutics, Inc. is an enzyme that causes the formation of 3-deoxyglucosone. 3-deoxyglucosone is an adversely reactive molecule that causes the formation of free radicals and AGEs, Diabetics suffering from blindness and kidney disease have elevated levels regardless of glucose levels or caloric intake. The agreement includes up-front and milestone payments.

Read at BioSpace.com

Related News

comments powered by Disqus
   
Obesity
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES